Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation.
OBJECTIVE
Stereotactic body radiation therapy (SBRT) provides excellent local control with acceptable toxicity for patients with early-stage non-small cell lung cancer. However, the efficacy and safety of SBRT for patients previously given thoracic radiation therapy is not known. In this study, we retrospectively reviewed outcomes after SBRT for recurrent disease among patients previously given radiation therapy to the chest.


METHODS
A search of medical records for patients treated with SBRT to the thorax after prior fractionated radiation therapy to the chest at The University of Texas M. D. Anderson Cancer Center revealed 36 such cases. The median follow-up time after SBRT was 15 months. The endpoints analyzed were overall survival, local control, and the incidence and severity of treatment-related toxicity.


RESULTS
SBRT provided in-field local control for 92% of patients; at 2 years, the actuarial overall survival rate was 59%, and the actuarial progression-free survival rate was 26%, with the primary site of failure being intrathoracic relapse. Fifty percent of patients experienced worsening of dyspnea after SBRT, with 19% requiring oxygen supplementation; 30% of patients experienced chest wall pain and 8% Grade 3 esophagitis. No Grade 4 or 5 toxic effects were noted.


CONCLUSIONS
SBRT can provide excellent in-field tumor control in patients who have received prior radiation therapy. Toxicity was significant but manageable. The high rate of intrathoracic failure indicates the need for further study to identify patients who would derive the most benefit from SBRT for this purpose.
Kelly
Patrick
P
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Balter
Peter A
PA
Rebueno
Neal
N
Sharp
Hadley J
HJ
Liao
Zhongxing
Z
Komaki
Ritsuko
R
Chang
Joe Y
JY
D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
Cancer. 2004 Oct 1;101(7):1623-31
15378503
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):117-25
16765528
Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1010-5
16115740
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1345-50
14630272
J Clin Oncol. 2005 Dec 1;23(34):8863-9
16314646
Cancer. 1982 Mar 1;49(5):865-8
7059924
J Thorac Oncol. 2006 Nov;1(9):1042-58
17409993
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):796-801
19427740
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):399-409
18556144
Int J Clin Oncol. 2005 Aug;10(4):247-50
16136369
J Clin Oncol. 2007 Mar 10;25(8):947-52
17350943
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):390-6
11872284
Ann Thorac Surg. 2008 Nov;86(5):1632-8; discussion 1638-9
19049763
Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1388-93
15050314
Cancer. 2002 Sep 1;95(5):1144-50
12209702
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1281-93
17126203
J Clin Oncol. 2007 Sep 10;25(26):4146-52
17827465
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31
16169670
J Clin Oncol. 2006 Oct 20;24(30):4833-9
17050868
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):967-71
18954709
Thorac Surg Clin. 2007 May;17(2):251-9
17626403
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92
18164849
J Natl Cancer Inst. 1998 Sep 16;90(18):1335-45
9747865
Am J Clin Oncol. 1993 Dec;16(6):482-8
8256761
J Clin Oncol. 2001 Feb 15;19(4):1056-63
11181669